Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor and high-dose melphalan before HCT in multiple myeloma
NCT02780609Phase 2Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Jul 2017
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of selinexor in multiple myeloma (MM), sponsored by Moffitt Cancer Center. Started Jul 2017; status: completed.
02
Drugs
selinexor
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02780609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02780609.